{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-25-000030","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.645648+00:00","generated_at":"2026-05-17T00:36:53.441847+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NeuroPace reports record Q3 revenue $27.4M (+30% YoY); raises FY2025 guidance","bullets":["Record quarterly revenue of $27.4M, up 30% YoY; RNS System revenue $22.6M (+31% YoY).","Gross margin expanded to 77.4% from 73.2% YoY; operating loss narrowed to $2.6M from $4.2M.","Net loss improved to $3.5M from $5.5M YoY; cash and short-term investments $60M.","Raised FY2025 revenue guidance to $97M-$98M (21-23% YoY growth) and gross margin to 76%-77%.","On track to submit NAUTILUS PMA supplement to FDA for IGE indication expansion by year-end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-25-000030","json":"https://secwatch.observer/filing/0001528287-25-000030.json","markdown":"https://secwatch.observer/filing/0001528287-25-000030.md","text":"https://secwatch.observer/filing/0001528287-25-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828725000030/0001528287-25-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828725000030/npce-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:36:53.441847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}